Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Intellia Therapeutics will present Phase 3 HAELO trial data for its CRISPR-based gene editing therapy lonvo-z in a late-breaking oral presentation at the EAACI 2026 Congress. The presentation, titled 'HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran,' is scheduled for June 13, 2026, and will be delivered by Dr. Danny Cohn.
Key figures
- Drug Name
- lonvoguran ziclumeran (lonvo-z)
- Phase Of Trial
- Phase 3
- Conference
- EAACI 2026
- Trial name
- HAELO
- Presentation type
- Late-Breaking Oral Presentation
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.